Neuropace Inc (NPCE)

$MDT How Next-Gen Implants Are Making Seizure Prevention Smarter and Safer Than Ever An implantable chip could soon spot early epilepsy signals and intervene, significantly enhancing patients’ quality of life. At the heart of this innovation are Spiking Neural Networks (SNNs), a form of artificial intelligence that mimics the brain’s efficiency. These neuromorphic implantables, built on SNNs, mark notable progress toward energy-efficient AI, contrasting with traditional Artificial Neural Networks (ANNs) that operate nonstop like constant light sources. SNNs, in contrast, utilize event-triggered “spikes” (brief electrical pulses), activating only as needed and thereby slashing energy use—a vital advantage for medical tools. Read more here if interested...https://neuromorphiccore.ai/how-next-gen-implants-are-making-seizure-prevention-smarter-and-safer-than-ever/ $BSX $ABT $NPCE $LIVN

$NPCE @Scoops1212 Will Trump and RFK save us?

NeuroPace, Inc. Secures $75 Million Credit Facility from MidCap Financial to Support Growth Initiatives Read more on $NPCE: https://www.quiverquant.com/news/NeuroPace%2C+Inc.+Secures+%2475+Million+Credit+Facility+from+MidCap+Financial+to+Support+Growth+Initiatives

$NPCE Taco time? @Scoops1212

$NPCE just unveiled promising one-year results from its NAUTILUS trial, but the stock tumbled 28.4%! 🤔 The RNS System shows promising potential for idiopathic generalized epilepsy, potentially expanding its market reach and driving revenue growth. Yet, the market reacted sharply — a mismatch? Discover why this could be a strategic opportunity or a cautionary tale 👉 https://www.zacks.com/commentary/2478445/npce-stock-tumbles-despite-positive-one-year-data-from-nautilus-trial?cid=sm-stocktwits-2-2478445-body&ADID=SYND_STOCKTWITS_TWEET_2_2478445_BODY

$NPCE bought a few shares to support my MAGA friend

$NPCE reports promising one-year results from its NAUTILUS trial, showcasing the RNS System's effectiveness in treating idiopathic generalized epilepsy with sustained seizure reduction. Read more: https://www.zacks.com/stock/news/2478445/npce-stock-tumbles-despite-positive-one-year-data-from-nautilus-trial?cid=sm-stocktwits-2-2478445-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2478445_TEASER

$NPCE their financials support that, but the FDA in big Pharma is still in control. President Trump and RFK Junior are fighting to change that, but it’s still always away. Big Pharma doesn’t even need to buy out the small companies, as the FDA is in their pocket. amazing!

HC Wainwright & Co. updates rating for NeuroPace ( $NPCE ) to Buy, target set at 18.

$NPCE was 16. Now 12xx. Kind of like 40

$NPCE the bottom line from the conference is that the device does work, but its not possible to design a fair study for this indication. The placebo group figures out quickly that they are non-responders and leaves to seek other treatments. No one is willing to endure seizures for 2 years for the sake of a study. What FDA does with this is anyone's guess...

$VXRT My recommendation $NPCE had a bad day today, missing on their results for the epilepsy treatment. Of course, there are bright spots in the report, but the lack of hitting a home run with a small pharma company results in a decent dip. I feel the stock will rebound, but it's going to take a little time. I apologize for anyone that bought in on the rising SP the last few weeks, as all indications were that things were going very well. I reckon, most people will not come on and own up to a bad day, but I'm here to say I'm sorry for the dip. I don't lose often. However, that is only the case, because I own it when I do, and keep pushing without holding any anger.

$NPCE Why is your English bad? What country are you posting from?

$NPCE The foreign bots are in full effect now. Their English isn't even close to convincing anyone they have a clue of what they are posting.

$NPCE havig the worst day in a year...mama mia

$NPCE You actually convince yourself that you have any insight on picking a stock? Maybe try to know the game a little and not just base your opinion on "President Trump" will kill everything. LOL

$NPCE You are very sharp to wait for them moment it hits a dip and then come on about "Tariffs." This just confirmed you have never made any money and enjoy being a Monday morning QB. Let me guess, another liberal against Trump trying to pin this on him.

$NPCE https://youtu.be/3p7Q1o3UD70

$RCKT $NPCE $SVRA Crashed!!

$NPCE other recommendations?

$NPCE tRump tariffs will kill this co

$NPCE NeuroPace NAUTILUS trial met primary 12-week post-implant safety endpoint NeuroPace announced the preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for treatment of individuals with drug-resistant idiopathic generalized epilepsy. The study successfully met its primary 12-week post-implant safety endpoint, demonstrating a low rate of serious adverse events related to the device and implant procedure, consistent with the established safety profile of the RNS System. The study did not reach statistical significance for the primary effectiveness endpoint in the overall study population, which was to show a longer time to a second generalized tonic-clonic seizure in the active stimulation group compared to the sham stimulation group. Importantly, however, the data did show a clinically meaningful and highly statistically significant response in the primary effectiveness endpoint within a subgroup of patients with lower baseline frequency of generalized tonic-clonic seizures which represented the majority of trial participants. While the study is not powered to show effectiveness in subgroups, this analysis suggests that there is a therapeutic and clinically meaningful benefit of the RNS System in a substantial subpopulation.